Applications, challenges and future directions of artificial intelligence in cardio‐oncology
European Journal of Clinical Investigation · 2025-04 · 55 (S1)
DOI: 10.1111/eci.14370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 07.04.2025. Verfasst von Francesco Ravera und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Artificial Intelligence, Cardiotoxicity, Medical Oncology, Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, 5x1000 IRCCS, Progetti di Rilevante Interesse Nazionale (PRIN) ID 20223XM78Z, Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Background
The management of cardiotoxicity related to cancer therapies has emerged as a significant clinical challenge, prompting the rapid growth of cardio‐oncology. As cancer treatments become more complex, there is an increasing need to enhance diagnostic and therapeutic strategies for managing their cardiovascular side effects.
Objective
This review investigates the potential of artificial intelligence (AI) to revolutionize cardio‐oncology by integrating diverse data sources to address the challenges of cardiotoxicity management.
Methods
We explore applications of AI in cardio‐oncology, focusing on its ability to leverage multiple data sources, including electronic health records, electrocardiograms, imaging modalities, wearable sensors, and circulating serum biomarkers.
Results
AI has demonstrated significant potential in improving risk stratification and longitudinal monitoring of cardiotoxicity. By optimizing the use of electrocardiograms, non‐invasive imaging, and circulating biomarkers, AI facilitates earlier detection, better prediction of outcomes, and more personalized therapeutic interventions. These advancements are poised to enhance patient outcomes and streamline clinical decision‐making.
Conclusions
AI represents a transformative opportunity in cardio‐oncology by advancing diagnostic and therapeutic capabilities. However, successful implementation requires addressing practical challenges such as data integration, model interpretability, and clinician training. Continued collaboration between clinicians and AI developers will be essential to fully integrate AI into routine clinical workflows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
ORCID-Profile: Francesco Ravera
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- 5x1000 IRCCS, Progetti di Rilevante Interesse Nazionale (PRIN) ID 20223XM78Z
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Ravera, F., Gilardi, N., Ballestrero, A., & Zoppoli, G. (2025). Applications, challenges and future directions of artificial intelligence in cardio‐oncology. European Journal of Clinical Investigation, 55(S1). https://doi.org/10.1111/eci.14370
Vancouver
Ravera F, Gilardi N, Ballestrero A, Zoppoli G. Applications, challenges and future directions of artificial intelligence in cardio‐oncology. European Journal of Clinical Investigation. 2025;55(S1). doi:10.1111/eci.14370
BibTeX
@article{Ravera2025,
author = {Ravera, Francesco and Gilardi, Nicolò and Ballestrero, Alberto and Zoppoli, Gabriele},
title = {Applications, challenges and future directions of artificial intelligence in cardio‐oncology},
journal = {European Journal of Clinical Investigation},
year = {2025},
volume = {55},
number = {S1},
doi = {10.1111/eci.14370}
}
EUVIMED